| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Flerie-Aktie nach Q3-Zahlen im Aufwind trotz Wertberichtigungen | 1 | Investing.com Deutsch | ||
| Mi | Flerie AB: Flerie AB (publ) Interim Report January - September 2025 | 38 | GlobeNewswire (Europe) | The period in brief• Net asset value was SEK 3,918 million (4,262) and net asset value per share was SEK 50.58 (54.59 at 30 September 2024). Change in net asset value per share in the quarter was -4.2... ► Artikel lesen | |
| 23.09. | Flerie AB: Flerie's portfolio company Xintela has presented positive 24-month data for its stem cell product XSTEM | 91 | GlobeNewswire (Europe) | Stockholm, Sweden, September 23, 2025. Flerie AB's (publ) portfolio company Xintela has announced that its stem cell product XSTEM continues to demonstrate safety, reduction in knee pain, improved joint... ► Artikel lesen | |
| 19.08. | Flerie AB: The merger between Flerie and Toleranzia has been completed | 125 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| FLERIE Aktie jetzt für 0€ handeln | |||||
| 08.08. | Toleranzia AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Toleranzia | 157 | GlobeNewswire (Europe) | The Swedish Companies Registration Office (Sw. Bolagsverket) has granted permission to Flerie AB (publ) ("Flerie") to carry out the merger plan concerning the merger between Flerie and Toleranzia AB... ► Artikel lesen | |
| 31.07. | Flerie AB: The Board of Directors of Flerie has resolved to redeem all Series C shares within the framework of Flerie's share redemption scheme | 109 | GlobeNewswire (Europe) | At an Extraordinary General Meeting of Flerie AB (publ) ("Flerie" or the "Company") held on 10 June 2024, a resolution was passed to introduce a redemption scheme for the Company's shares. Redemption... ► Artikel lesen | |
| 31.07. | Flerie AB: Flerie AB (publ) Interim Report January - June 2025 | 131 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 4,121 million (4,380) and net asset value per share was SEK 52.78 (SEK 56.10 at 30 June 2024). Change in net asset value per share in the quarter was 4.4 per... ► Artikel lesen | |
| 16.07. | Flerie AB: Flerie AB's subsidiary Flerie Invest AB announces final outcome of the mandatory cash offer to the shareholders of Nanologica AB (publ) | 503 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
| 25.06. | Toleranzia AB: Toleranzia applies for delisting of the Company's shares from Nasdaq First North Growth Market, conditional upon completion of the merger with Flerie | 123 | GlobeNewswire (Europe) | Toleranzia AB (publ) ("Toleranzia" or the "Company") has today, in connection with the upcoming merger between Toleranzia and Flerie (the "Merger"), which was announced through a press release on 25... ► Artikel lesen | |
| 13.06. | Nanologica AB: Statement From The Board Of Directors Of Nanologica AB (publ) Regarding The Mandatory Bid From Flerie Invest Ab | 568 | GlobeNewswire (Europe) | The Board of Directors of Nanologica AB (publ) ("Nanologica" or the "Company") unanimously recommends the shareholders of Nanologica not to accept the mandatory cash offer made by Flerie Invest AB ("Flerie")... ► Artikel lesen | |
| 12.06. | Flerie AB: Flerie's portfolio company Nanologica has received its first U.S. order | 732 | GlobeNewswire (Europe) | Stockholm, Sweden, June 12, 2025. Flerie AB's (publ) portfolio company Nanologica has announced that the company has secured an order for its silica-based purification media, NLAB Saga®, from a new... ► Artikel lesen | |
| 03.06. | Flerie AB: Flerie's portfolio company KAHR Bio presents positive results from its Phase II trial with DSP107 in combination with anti-PD-L1 in colorectal cancer | 101 | GlobeNewswire (Europe) | Stockholm, Sweden, June 3, 2025. Flerie AB's (publ) portfolio company KAHR Bio has communicated that they have presented positive Phase II results at the 2025 ASCO Annual Meeting.
The results indicate... ► Artikel lesen | |
| 23.05. | Nanologica AB: Comment from the Board of Nanologica AB (publ) Regarding the Mandatory Bid from Flerie Invest AB | 892 | GlobeNewswire (Europe) | Nanologica AB's (publ) ("Nanologica") main owner Flerie Invest AB ("Flerie") has today, May 23, 2025, made a mandatory cash offer of SEK 1.00 per share to the shareholders of Nanologica (the "Offer").... ► Artikel lesen | |
| 23.05. | Flerie AB: Flerie Invest AB announces a mandatory cash offer to the shareholders of Nanologica AB (publ) | 895 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
| 14.05. | Flerie AB: The General Meetings of Flerie and Toleranzia respectively have approved the merger plan and the General Meeting in Flerie has resolved on issuance of the merger consideration | 118 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 30.04. | Flerie AB: Flerie receives FDI-approval for the merger with Toleranzia | 266 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 26.04. | Nanologica AB: Nanologica AB Informs that Flerie Invest AB has Passed the Threshold for Mandatory Bid | 824 | GlobeNewswire (Europe) | Nanologica's main owner Flerie Invest AB ("Flerie") has acquired additional shares in Nanologica AB with the result that a mandatory bid obligation has arisen. Flerie's total holding in Nanologica after... ► Artikel lesen | |
| 16.04. | Flerie AB: Flerie AB Interim Report January - March 2025 | 157 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,947 million (3,416) and net asset value per share was SEK 50.56 (56.24), adjusted net asset value per share was 51.88 (56.24). Change in net asset value... ► Artikel lesen | |
| 14.04. | Flerie AB: Flerie's portfolio company Lipum presents positive results from its Phase I trial with SOL-116 | 199 | GlobeNewswire (Europe) | Stockholm, Sweden, April 14, 2025. Flerie AB announces that its portfolio company Lipum has presented final results from a Phase I trial evaluating SOL-116 in healthy volunteers and patients with rheumatoid... ► Artikel lesen | |
| 25.03. | Toleranzia AB: Statement by the Board of Directors of Toleranzia in view of the merger offer by Flerie | 249 | GlobeNewswire (Europe) | The Board of Directors of Toleranzia AB (publ) ("Toleranzia") unanimously recommends the shareholders of Toleranzia to vote in favour of the completion of the merger between Toleranzia and Flerie AB... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HAEMATO | 10,300 | -1,90 % | EQS-Adhoc: M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Verkauf/Beteiligung/Unternehmensbeteiligung
M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group
16.10.2025... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 10,275 | -0,19 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema | - DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 - - New preclinical... ► Artikel lesen | |
| PHOTOCURE | 4,385 | 0,00 % | Photocure ASA: Invitation to presentation of third quarter 2025 financial results | ||
| BAYER | 27,775 | +0,71 % | Fast 150 % Kurschance! Plug Power, Bayer, Planethic Group Aktie | Bietet sich bei der Planethic Group (vormals Veganz Group) die Kaufchance des Herbstes? Analysten sehen jedenfalls über 100 % Kurspotenzial. Die jüngste Korrektur scheint übertrieben und lockt zum Einstieg.... ► Artikel lesen | |
| MERCK KGAA | 115,05 | -0,17 % | UBS stuft MERCK KGAA auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Merck KGaA nach dem Kapitalmarkttag von 154 auf 150 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Matthew Weston reduzierte... ► Artikel lesen | |
| NOVO NORDISK | 45,765 | +0,19 % | Rheinmetall: Ziel 1.500 Euro? - BYD, Circus, Evotec, Novo Nordisk und stock3 im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| WELLGISTICS HEALTH | 1,140 | +180,30 % | Datavault AI Inc.: DataVault AI and Wellgistics Health Announce Plans for PharmacyChain to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency and ... | BEAVERTON, Ore., Oct. 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- DataVault AI, Inc. ("DataVault") (NASDAQ: DVLT), leading the way in AI data experience, valuation, and monetization, and Wellgistics Health... ► Artikel lesen | |
| SANOFI | 88,72 | +0,15 % | Tagesvorschau: 24. Oktober: Finale der Berichtswoche mit Porsche, Sanofi & Co. | Bilanz-Endspurt und globale StimmungsprobenZum Wochenschluss rücken Porsche, Sanofi, Holcim und Safran in den Fokus - die europäischen Schwergewichte beschließen die Berichtssaison. Die globale Stimmung... ► Artikel lesen | |
| GSK | 18,570 | -2,13 % | GSK und US-Partner Alector stellen Tests an Demenzmittel nach Studienflop ein | LONDON (dpa-AFX) - Der Pharmakonzern GSK hat einen Flop bei seinen Forschungsarbeiten an einem Demenzmittel erlitten. Wie das Unternehmen am Mittwoch zusammen mit seinem Partner Alector verkündete... ► Artikel lesen | |
| PFIZER | 21,325 | +0,12 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer nach starken EV-303-Studiendaten mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Analyst Chris Schott wertete... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,348 | +2,75 % | Theriva Biologics, Inc.: Theriva Biologics Provides Response to Unusual Market Action | ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat... ► Artikel lesen | |
| ASTRAZENECA | 143,40 | 0,00 % | AstraZeneca: Brustkrebs-Erfolg trifft Analysten-Skepsis | Der Aktienkurs von AstraZeneca steht derzeit bei 144,60 EUR und zeigt sich stabil - trotz eines Verkaufsratings der Deutschen Bank, das vergangene Woche für kurzfristige Verunsicherung sorgte. Der britisch-schwedische... ► Artikel lesen | |
| SCHOTT PHARMA | 20,000 | -1,23 % | EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: SCHOTT Pharma AG & Co. KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
SCHOTT Pharma AG & Co. KGaA:... ► Artikel lesen | |
| ELI LILLY | 716,60 | +1,36 % | Märkte am Morgen: Thyssenkrupp Marine Systems, Novo Nordisk/Eli Lilly, American Express, L'Oreal | Der DAX ist zum Ende der vergangenen Woche deutlich unter die Räder gekommen. Am Freitag gab er über 1,8 Prozent ab. Befürchtungen um eine mögliche Bankenkrise in den USA machen die Runde. Heute deutet... ► Artikel lesen | |
| MERCK & CO | 75,40 | +0,27 % | 7,25% Vontobel-Aktienanleihe auf Merck & Co, Novartis, Roche: Pharma-Giganten im Wandel - Anleiheanalyse | München (www.anleihencheck.de) - Die globale Pharmaindustrie steht vor einer neuen Ära, geprägt von biotechnologischen Innovationen, steigenden Gesundheitsausgaben und wachsender Nachfrage nach individualisierten... ► Artikel lesen |